These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 12750277)

  • 1. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
    Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
    J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
    Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
    Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
    Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
    Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
    Lee PP; Yee C; Savage PA; Fong L; Brockstedt D; Weber JS; Johnson D; Swetter S; Thompson J; Greenberg PD; Roederer M; Davis MM
    Nat Med; 1999 Jun; 5(6):677-85. PubMed ID: 10371507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
    Valmori D; Scheibenbogen C; Dutoit V; Nagorsen D; Asemissen AM; Rubio-Godoy V; Rimoldi D; Guillaume P; Romero P; Schadendorf D; Lipp M; Dietrich PY; Thiel E; Cerottini JC; Liénard D; Keilholz U
    Cancer Res; 2002 Mar; 62(6):1743-50. PubMed ID: 11912149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
    Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
    Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
    Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation.
    Viallard JF; Blanco P; André M; Etienne G; Liferman F; Neau D; Vidal E; Moreau JF; Pellegrin JL
    Clin Immunol; 2006 Apr; 119(1):51-8. PubMed ID: 16413828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
    Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
    Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.